[In vitro sensitivity of Plasmodium falciparum to mefloquine, quinine, amodiaquine, chloroquine, pyronaridine and sulfadoxine/pyrimethamine in south Yunnan].
The sensitivity of P. falciparum to mefloquine, quinine, amodiaquine, chloroquine, pyronaridine, and sulfadoxine/pyrimethamine (MEF, QNN, AMO, CHL, PYR, S/P) was tested using in vitro microtest in south Yunnan Province in 1992. The ID50 were 46, 480, 52, 150, 15 and 2 x 10(4)/25 x 10(2) nmol/L, respectively; ID95 were 160, 1,536, 292, 680, 60 and 24 x 10(5)/3 x 10(5) nmol/L, respectively. All the isolates (30) were sensitive to MEF and QNN; 100% (30/30) and 96.7% (29/30) isolates were found to be resistant to AMO and CHL, the cross-resistance rate was 100% to the two drugs. One of 5 isolates exhibited resistance to PYR. The results suggest that the P. falciparum was susceptible to MEF and QNN, but was resistant to AMO, CHL and S/P. CHL-resistant P. falciparum showed a marked cross-resistance to AMO, but not to MEF, QNN, and S/P; AMO-resistant P. falciparum exhibited cross-resistance to CHL, but not to MEF, QNN, and S/P.
Institute of Malaria Prevention and Treatment of Yunnan Province, Simao.
H
H
Yang
P
P
Yang
Y
Y
Yang
D000655:Amodiaquine / Q000494:pharmacology; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D002738:Chloroquine / Q000494:pharmacology; D004338:Drug Combinations; D004351:Drug Resistance; D015767:Mefloquine / Q000494:pharmacology; D009287:Naphthyridines / Q000494:pharmacology; D010963:Plasmodium falciparum / Q000187:drug effects*; D011739:Pyrimethamine / Q000494:pharmacology; D011803:Quinine / Q000494:pharmacology; D013413:Sulfadoxine / Q000494:pharmacology
D000962:Antimalarials; D004338:Drug Combinations; D009287:Naphthyridines; D000655:Amodiaquine; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011803:Quinine; C027871:pyronaridine; D015767:Mefloquine; D011739:Pyrimethamine